An early human study suggests immunotherapy for glioblastoma may require targeting the immune suppressive effects of MDSCs along with immune activation tactics to overcome tumor-induced immunosuppression.
Researchers seek to reduce tumor growth by inhibiting activity of immunosuppressive cells called myeloid-derived suppressor cells. The goal: new therapies that overcome glioblastoma’s therapeutic resistance.
Emerging sex differences in multiple aspects of this lethal brain cancer likely help explain the disease’s more favorable incidence and prognosis in females. And they may point to new targeted therapies.
A leading clinician-researcher profiles clinical trials of mechanistically diverse treatment strategies to combat glioblastoma. All four stem from Cleveland Clinic’s robust translational collaborations in this space.